Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MOLN NASDAQ:PVLA NASDAQ:SIGA NASDAQ:TRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMOLNMolecular Partners$3.72+0.0%$3.70$3.36▼$7.60$150.19M1.15,009 shs2,889 shsPVLAPalvella Therapeutics$59.73+5.3%$41.42$11.17▼$60.97$627.19M-0.03124,697 shs89,476 shsSIGASiga Technologies$8.72-0.5%$7.76$4.95▼$9.62$627.27M0.95520,342 shs538,673 shsTRMLTourmaline Bio$47.60-0.1%$22.30$11.56▼$47.69$1.22B2.041.33 million shs3.13 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMOLNMolecular Partners-1.43%-0.13%+1.50%-4.59%-33.67%PVLAPalvella Therapeutics+5.33%+11.62%+43.20%+126.08%+5,972,999,900.00%SIGASiga Technologies-0.46%+1.28%-8.02%+35.40%+15.50%TRMLTourmaline Bio-0.08%+89.57%+126.77%+139.20%+169.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMOLNMolecular Partners$3.72+0.0%$3.70$3.36▼$7.60$150.19M1.15,009 shs2,889 shsPVLAPalvella Therapeutics$59.73+5.3%$41.42$11.17▼$60.97$627.19M-0.03124,697 shs89,476 shsSIGASiga Technologies$8.72-0.5%$7.76$4.95▼$9.62$627.27M0.95520,342 shs538,673 shsTRMLTourmaline Bio$47.60-0.1%$22.30$11.56▼$47.69$1.22B2.041.33 million shs3.13 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMOLNMolecular Partners-1.43%-0.13%+1.50%-4.59%-33.67%PVLAPalvella Therapeutics+5.33%+11.62%+43.20%+126.08%+5,972,999,900.00%SIGASiga Technologies-0.46%+1.28%-8.02%+35.40%+15.50%TRMLTourmaline Bio-0.08%+89.57%+126.77%+139.20%+169.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMOLNMolecular Partners 3.00Buy$8.00115.00% UpsidePVLAPalvella Therapeutics 3.08Buy$60.911.97% UpsideSIGASiga Technologies 0.00N/AN/AN/ATRMLTourmaline Bio 2.22Hold$45.61-4.18% DownsideCurrent Analyst Ratings BreakdownLatest MOLN, TRML, SIGA, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025TRMLTourmaline BioTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$63.00 ➝ $48.009/10/2025TRMLTourmaline BioGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$55.00 ➝ $48.009/10/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$50.00 ➝ $48.009/10/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$70.00 ➝ $48.009/9/2025TRMLTourmaline BioGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold9/9/2025PVLAPalvella TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$85.009/9/2025TRMLTourmaline BioJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$64.00 ➝ $47.509/9/2025TRMLTourmaline BioLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$48.009/9/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$48.009/3/2025MOLNMolecular PartnersJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$4.50 ➝ $4.008/19/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $66.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMOLNMolecular Partners$5.65M26.59N/AN/A$3.99 per share0.93PVLAPalvella Therapeutics$42.81M15.43N/AN/A$5.58 per share10.70SIGASiga Technologies$138.72M4.50$0.83 per share10.47$3.02 per share2.89TRMLTourmaline BioN/AN/AN/AN/A$11.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMOLNMolecular Partners-$61.39M-$2.08N/AN/AN/AN/A-50.66%-45.13%10/30/2025 (Estimated)PVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-62.30%-43.34%11/12/2025 (Estimated)SIGASiga Technologies$59.21M$1.137.726.98N/A45.73%40.52%35.62%11/6/2025 (Estimated)TRMLTourmaline Bio-$73.21M-$3.43N/AN/AN/AN/A-30.50%-29.63%11/6/2025 (Estimated)Latest MOLN, TRML, SIGA, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/25/2025H1 2025MOLNMolecular Partners-$0.53-$0.67-$0.14-$0.67N/AN/A8/14/2025Q2 2025PVLAPalvella Therapeutics-$0.78-$0.86-$0.08-$0.86N/AN/A8/13/2025Q2 2025TRMLTourmaline Bio-$0.94-$0.90+$0.04-$0.90N/AN/A8/5/2025Q2 2025SIGASiga TechnologiesN/A$0.49N/A$0.49N/A$81.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMOLNMolecular PartnersN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMOLNMolecular PartnersN/A9.359.35PVLAPalvella TherapeuticsN/A7.677.67SIGASiga TechnologiesN/A10.098.52TRMLTourmaline BioN/A24.6824.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMOLNMolecular Partners26.55%PVLAPalvella Therapeutics40.11%SIGASiga Technologies55.40%TRMLTourmaline Bio91.89%Insider OwnershipCompanyInsider OwnershipMOLNMolecular Partners5.93%PVLAPalvella Therapeutics20.50%SIGASiga Technologies1.95%TRMLTourmaline Bio13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionablePVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/ASIGASiga Technologies4071.61 million70.21 millionOptionableTRMLTourmaline Bio4425.69 million22.35 millionOptionableMOLN, TRML, SIGA, and PVLA HeadlinesRecent News About These CompaniesTourmaline Bio's (TRML) Neutral Rating Reaffirmed at Guggenheim1 hour ago | americanbankingnews.comTourmaline Bio (NASDAQ:TRML) Receives "Market Perform" Rating from Lifesci Capital3 hours ago | americanbankingnews.comTourmaline Bio (NASDAQ:TRML) Downgraded to Neutral Rating by Wedbush3 hours ago | americanbankingnews.comJefferies Financial Group Reiterates Hold Rating for Tourmaline Bio (NASDAQ:TRML)3 hours ago | americanbankingnews.comHC Wainwright & Co. Downgrades Tourmaline Bio (TRML)September 10 at 3:33 PM | msn.comTourmaline Bio (NASDAQ:TRML) Hits New 52-Week High - Still a Buy?September 10 at 12:16 PM | marketbeat.comNVS to Acquire TRML, Add Phase III Cardiovascular Drug to PipelineSeptember 10 at 12:11 PM | zacks.comLifeSci Capital Downgrades Tourmaline Bio (TRML)September 10 at 8:41 AM | msn.comAnalysts Set Tourmaline Bio, Inc. (NASDAQ:TRML) Price Target at $50.14September 10 at 2:33 AM | americanbankingnews.comThis Small Biotech Stock Is Surging Today. Here's Why.September 9 at 12:35 PM | investopedia.comNovartis to acquire Tourmaline Bio for $1.4 billionSeptember 9 at 8:26 AM | msn.comNovartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio AcquisitionSeptember 9 at 8:26 AM | finance.yahoo.comTRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to ShareholdersSeptember 9 at 5:41 AM | businesswire.comAdage Capital Partners GP L.L.C. Cuts Stock Holdings in Tourmaline Bio, Inc. $TRMLSeptember 9 at 4:32 AM | marketbeat.comNovartis strikes $1.4bn deal for Tourmaline BioSeptember 9 at 3:02 AM | proactiveinvestors.co.ukShareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public ShareholdersSeptember 9 at 2:43 AM | businesswire.comNovartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar DealSeptember 9 at 2:02 AM | wsj.comNovartis to acquire Tourmaline Bio in deal valuing it at $1.4 billionSeptember 9 at 2:15 AM | reuters.comNovartis to Acquire Tourmaline Bio for $1.4 Billion, Enhancing Cardiovascular Treatment PortfolioSeptember 9 at 2:11 AM | quiverquant.comQTourmaline Bio Enters into Agreement to be Acquired by Novartis AGSeptember 9 at 2:03 AM | globenewswire.comNovartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)September 9 at 2:00 AM | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMOLN, TRML, SIGA, and PVLA Company DescriptionsMolecular Partners NASDAQ:MOLN$3.72 +0.00 (+0.03%) Closing price 09/10/2025 03:55 PM EasternExtended Trading$3.75 +0.03 (+0.75%) As of 09/10/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Palvella Therapeutics NASDAQ:PVLA$59.73 +3.02 (+5.33%) As of 09/10/2025 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Siga Technologies NASDAQ:SIGA$8.72 -0.04 (-0.46%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$8.50 -0.22 (-2.52%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.Tourmaline Bio NASDAQ:TRML$47.60 -0.04 (-0.08%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$47.44 -0.16 (-0.35%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
